{"ticker": {"uuid": "17bb16ae-0669-4cc3-a11b-3c5d9d18d48c", "symbol": "NTLA", "name": "Intellia Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOSEhIMHl0Xzd3R1BUbEFZVVlNSDE3THFsUnRXem54akl1YWNnSUxDa3JHZWd4YlFlaUs4a3JnNVNaRGx6MTR3N1N3by1UWHJtZFBzTlEyUFBVbW4tLUhJV1JRaFh4QTE5R05CSTZOZlN3OWFhdC1PUnFBNHVjbzJsVGR4ZHFNOS1NVTFMQ0VjbFMxM1dBSUpxdWFjUEhLU3hhZjZkeHlFeVIxUXFVZG9wM0pFSkd3eEJYLVZSTlY1VjU0X25xWFU5dG5B?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-22T08:45:11+00:00", "published_display": "22 Jun 2026 08:45", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Positive Phase III Data Sells Investors on Intellia", "summary": "Intellia Therapeutics' shares surged after positive Phase III data for its gene-editing candidate, lonvoguran ziclumeran (lonvo-z), in hereditary angioedema (HAE). The therapy met primary and secondary endpoints, leading analysts to anticipate FDA approval and strong market adopt", "url": "https://www.genengnews.com/topics/translational-medicine/stockwatch-positive-phase-iii-data-sells-investors-on-intellia/", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-06-22T00:40:24", "published_display": "22 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNOGN5ekxXVGRDQkVHYXI1ZERGYm91aG1GRHpSY2RKeGF4N0J1UXJ2TVJYaEc1Z3lnSG9kUXE4bHRCRHJmajYxOU00LUdDenh0LU5ETXJZdVQ0ZllUZHVIV1I0X0c3Qm9QNmx6UmZEeFREWFZia0psaTVzbkRacHVHVUdoVjRrcXplOXM0VWtoWWNQamh3WC0zTGs3WGgtaXA3bHM1blpqTFB3R3phNUxVR0tn?oc=5", "source_name": "Kavout", "published_at": "2026-06-21T22:42:58+00:00", "published_display": "21 Jun 2026 22:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA Filing", "summary": "Intellia Therapeutics (NTLA) shares surged 29.4% following positive Phase 3 HAELO trial data for its CRISPR therapy, lonvo-z, targeting hereditary angioedema. The company also filed a rolling biologics license application with the FDA and published results in the New England Jour", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-up-294-after-new-phase-3-lonvo", "source_name": "Simply Wall Street", "published_at": "2026-06-21T20:39:36", "published_display": "21 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/d1b7d197-3672-3b18-947e-fbf48989e2a9/intellia-therapeutics-vs..html", "source_name": "Motley Fool", "published_at": "2026-06-20T15:22:04+00:00", "published_display": "20 Jun 2026 15:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Stock Could Be 41.2% Undervalued After Phase 3 HAE Data", "summary": "Intellia Therapeutics (NTLA) is drawing attention after releasing positive Phase 3 HAELO trial data for its CRISPR-based therapy lonvo-z in hereditary angioedema and submitting a rolling biologics license application to the FDA. Despite a recent 70.14% year-to-date share price in", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-stock-could-be-412-undervalued-af/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-19T23:09:04", "published_display": "19 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price", "summary": "Intellia Therapeutics (NTLA) saw a significant stock price surge of 10.7% on June 17, 2026, driven by increased investor confidence in its CRISPR/Cas9 gene-editing technology. Despite a solid GF Score\u2122 of 72, indicating strong growth prospects, the company's low profitability ran", "url": "https://www.gurufocus.com/news/8920894/intellia-therapeutics-ntla-sees-107-surge-in-stock-price?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-17T20:09:38", "published_display": "17 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads", "summary": "Intellia Therapeutics Inc. (NTLA) stock surged by 10.24% following promising Phase 3 CRISPR gene-editing trial results for its drug lonvo-z, aimed at hereditary angioedema. The data, published in the New England Journal of Medicine and presented at EAACI 2026, showed significant ", "url": "https://stockstotrade.com/news/intellia-therapeutics-inc-ntla-news-2026_06_17/", "source_name": "StocksToTrade", "published_at": "2026-06-17T17:42:16", "published_display": "17 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia\u2019s gene editor \u2018keeps pace\u2019 with Ionis in hereditary angioedema", "summary": "Intellia Therapeutics' CRISPR-based gene editing therapy, lonvo-z, showed significant efficacy in a Phase 3 study for hereditary angioedema, reducing disease attack episodes by 89% and moderate/severe attacks by 91%. Analysts predict lonvo-z could challenge Ionis Pharmaceuticals'", "url": "https://www.biospace.com/drug-development/intellias-gene-editor-keeps-pace-with-ionis-in-hereditary-angioedema", "source_name": "BioSpace", "published_at": "2026-06-16T22:40:18", "published_display": "16 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up", "summary": "Intellia Therapeutics (NTLA) shares surged 23.2% after announcing additional positive data from its phase III HAELO study for lonvo-z, an HAE gene-editing therapy. The latest data showed lonvo-z significantly reduced the monthly rates of HAE attacks, further demonstrating its pot", "url": "https://www.tradingview.com/news/zacks:3c8d58e84094b:0-ntla-posts-strong-additional-phase-iii-data-from-hae-study-stock-up/", "source_name": "TradingView", "published_at": "2026-06-16T14:39:09", "published_display": "16 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?", "summary": "Intellia Therapeutics (NTLA) shares surged 23.2% after", "url": "https://au.finance.yahoo.com/news/strength-seen-intellia-therapeutics-ntla-124300834.html", "source_name": "Market source", "published_at": "2026-06-16T12:43:00", "published_display": "16 Jun 2026 12:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)", "summary": "This article highlights recent analyst ratings for several healthcare companies. Wells Fargo maintained a Hold rating on Incyte (INCY), while TD Cowen and William Blair reiterated Buy ratings for Intellia Therapeutics (NTLA). Wells Fargo also maintained a Hold rating on Halozyme ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/INCY/pressreleases/2489035/analysts-conflicted-on-these-healthcare-names-incyte-incy-intellia-therapeutics-ntla-and-halozyme-halo/", "source_name": "The Globe and Mail", "published_at": "2026-06-16T10:39:09", "published_display": "16 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results", "summary": "Intellia Therapeutics saw its share price jump 23% following positive Phase 3 results for its hereditary angioedema (HAE) treatment, Lonvo-Z. The drug achieved an 87% reduction in monthly attacks compared to placebo and demonstrated favorable safety, with 62% of patients being at", "url": "https://finance.yahoo.com/healthcare/articles/intellia-therapeutics-ntla-skyrockets-23-024604431.html", "source_name": "Market source", "published_at": "2026-06-16T03:10:41", "published_display": "16 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?", "summary": "", "url": "https://finance.yahoo.com/m/724376ea-3984-3ab1-9ac0-3ce9b78fd1fe/intellia-surges%3B-can-its.html", "source_name": "Investor's Business Daily", "published_at": "2026-06-15T21:10:35+00:00", "published_display": "15 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com", "summary": "Intellia Therapeutics Inc.'s options trading volume significantly increased to 7,041 contracts on Monday morning, with call options representing the majority of the activity. The June 18, 2026 $13 and $14 call options saw substantial contract volumes. Shares of Intellia Therapeut", "url": "https://ng.investing.com/news/stock-market-news/intellia-therapeutics-options-trading-jumps-to-7041-contracts-93CH-2558703", "source_name": "Investing.com Nigeria", "published_at": "2026-06-15T16:09:26", "published_display": "15 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9", "summary": "Goldman Sachs has reiterated its Sell rating for Intellia Therapeutics (NTLA.US), keeping the target price at $9. This indicates a continued bearish outlook from the investment bank on the company's stock.", "url": "https://www.moomoo.com/news/post/71545619/goldman-sachs-maintains-intellia-therapeutics-ntlaus-with-sell-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-15T16:09:26", "published_display": "15 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder", "summary": "Intellia Therapeutics' gene-editing therapy, lonvo-z (previously NTLA-2002), has shown promising results in its Phase 3 HAELO trial for hereditary angioedema (HAE), demonstrating an 87% reduction in monthly HAE attacks compared to placebo. The data, presented at EAACI 2026 and pu", "url": "https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/06/53194250/intellias-one-time-gene-editing-therapy-gains-ground-against-rivals-in-rare-swelling-disorder", "source_name": "Benzinga", "published_at": "2026-06-15T14:09:26", "published_display": "15 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia touts \u2018paradigm-shifting\u2019 phase 3 data for one-time HAE treatment", "summary": "Intellia Therapeutics has released additional positive phase 3 data for its one-time gene-editing therapy, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE). The results showed significant reductions in HAE attacks and improvements in quality of life, meeting secon", "url": "https://www.fiercebiotech.com/biotech/intellia-shares-paradigm-shifting-ph-3-data-one-time-treatment-hae-patients", "source_name": "Fierce Biotech", "published_at": "2026-06-15T10:37:00", "published_display": "15 Jun 2026 10:37", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is NTLA Stock Jumping 5% Premarket Today?", "summary": "Intellia Therapeutics (NTLA) stock surged 5% premarket after releasing additional Phase 3 data for its CRISPR-based hereditary angioedema (HAE) treatment, Lonvo-z. The data showed an 89% reduction in attacks requiring rescue medication and significant quality-of-life improvements", "url": "https://stocktwits.com/news-articles/markets/equity/why-is-ntla-stock-jumping-premarket-today/cZKfOwMR7dV", "source_name": "Stocktwits", "published_at": "2026-06-15T08:14:37", "published_display": "15 Jun 2026 08:14", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Intellia Therapeutics (NTLA) Is Down 10.6% After Advancing Lonvo-z Toward FDA Review And Commercialization", "summary": "Intellia Therapeutics (NTLA) recently reported positive Phase 3 results for its gene-editing therapy, lonvo-z, for hereditary angioedema and has initiated a rolling biologics license application with the FDA. Despite this significant progress towards potential commercialization, ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-106-after-advancing-l", "source_name": "Simply Wall Street", "published_at": "2026-06-14T12:39:54", "published_display": "14 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound?", "summary": "This article discusses the recent performance of Intellia Therapeutics (NTLA), noting a 7.9% decline since its last earnings report. The piece poses the question of whether the stock can rebound from this downturn.", "url": "https://www.msn.com/en-us/money/topstocks/intellia-therapeutics-ntla-down-79-since-last-earnings-report-can-it-rebound/ar-AA25jckm", "source_name": "MSN", "published_at": "2026-06-13T20:39:54", "published_display": "13 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema", "summary": "Intellia Therapeutics announced additional positive Phase 3 results for lonvoguran ziclumeran (lonvo-z), its CRISPR-based investigational treatment for hereditary angioedema (HAE). The data from the HAELO clinical trial, presented at EAACI 2026 and published in The New England Jo", "url": "https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3", "source_name": "Intellia Therapeutics", "published_at": "2026-06-13T12:09:42", "published_display": "13 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Reports Additional Positive Phase 3 Results For Lonvoguran Ziclumeran (Lonvo-Z)", "summary": "Intellia Therapeutics announced additional positive Phase 3 results for its drug Lonvoguran Ziclumeran (Lonvo-Z). The announcement indicates progress for the company in its clinical trials. The news is brief and provided by Refinitiv.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA8CD8VW:0-intellia-therapeutics-says-haleo-met-its-primary-endpoint-with-an-87-reduction-p-0-0001-in-mean-monthly-attacks-in-lonvo-z-arm/", "source_name": "TradingView", "published_at": "2026-06-13T11:09:42", "published_display": "13 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial", "summary": "Intellia Therapeutics reported additional positive Phase 3 HAELO data for its CRISPR gene-editing treatment, lonvo-z, showing an 87% reduction in mean monthly hereditary angioedema (HAE) attacks compared to placebo. The trial also demonstrated a significant improvement in quality", "url": "https://www.stocktitan.net/news/NTLA/intellia-therapeutics-reports-additional-positive-phase-3-results-afks73wvycew.html", "source_name": "Stock Titan", "published_at": "2026-06-13T11:09:42", "published_display": "13 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploring High Growth Tech Stocks In The US Market", "summary": "This article identifies and discusses high-growth tech stocks in the US market, noting the market's recent decline but overall annual growth. It highlights key companies like LightPath Technologies, Intellia Therapeutics, and AppLovin, detailing their financial performance, growt", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/exploring-high-growth-tech-stocks-in-the-us-market-25/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-11T11:12:19", "published_display": "11 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options", "summary": "Intellia Therapeutics (NTLA) director Muna Bhanji was granted 9,200 Restricted Stock Units (RSUs) and 13,300 stock options, as detailed in a recent Form 4 filing. The RSUs increase her direct common stock holdings to 36,403 shares, while the stock options have an exercise price o", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-013839da4612.html", "source_name": "Stock Titan", "published_at": "2026-06-11T07:39:32", "published_display": "11 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Goff Brian", "summary": "This article is a Form 4 statement from Intellia Therapeutics, detailing changes in beneficial ownership of securities for Director Brian Goff, as required by the SEC.", "url": "https://www.moomoo.com/news/notice/307505294/intellia-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-11T04:10:05", "published_display": "11 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) director Georgia Keresty receives stock awards and options grant", "summary": "Intellia Therapeutics director Georgia Keresty received equity compensation, including 9,200 restricted stock units (RSUs) and stock options for 13,300 shares at an exercise price of $12.89 per share. Following these grants, her direct holdings in common stock increased to 41,083", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-ff1dd5f15e40.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:10:05", "published_display": "10 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) director receives 9,200 RSUs and 13,300 options", "summary": "Intellia Therapeutics director Frank Verwiel was granted 9,200 restricted stock units (RSUs) and a stock option for 13,300 shares, reflecting new equity awards rather than open-market transactions. Following these grants, Verwiel directly holds 35,148 common shares and the new st", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-9db79714028e.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:10:05", "published_display": "10 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options", "summary": "Intellia Therapeutics director Fred E. Cohen was granted 9,200 restricted stock units and a stock option for 13,300 shares, according to a recent SEC Form 4 filing. The RSUs increase his direct common stock holdings to 216,653 shares, while the stock option has an exercise price ", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-8502e3800dbb.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:10:05", "published_display": "10 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) director awarded RSUs and stock options in new grant", "summary": "Intellia Therapeutics director William J. Chase received new equity awards on June 9, 2026, comprising 9,200 restricted stock units and stock options for 13,300 shares at an exercise price of $12.89. The stock options vest fully on the earlier of one year from the grant date or t", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-3c9b98311aa4.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:10:05", "published_display": "10 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNNXR5dFRBNkk0Q3NRTWpzQzNka2xSQTJDWi1vbkhybDExc0EzVGtkQXJIRGo5Y3Q4STlqbUZwREJhNVlsN050Q1dEOEdJUWRGTHVJZnZIUS0zSVptUzQtT1RKWl9LRkRNOHZ3akhqSDNoYjRiZFFZOHNtbkZMU1BKazhxZjNVdXJmT1BhcGZReUotQVR0UzhkVDZ3U1c2SE5LaTBOMnNn?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOTnMzbWZrVlVJMGhsdXc4aGpjdXp0c2pZSnMyTGl2MTRWRHVONDcxNXNlc0FUVWdET1BWR2NJdzFLUkZrUDdaU0lVcUE4eU9YU09HYTBzYlVwck80cVNON2llckx5Wk1IbUtrMHRsYlZWdk9XZWs1RTJjYVJGZzdtMEtmY2hRU2E2LWlWS0tMaERsN1JhcFNhMHVVSEZoX1hQ?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPa2JqcDFJbXFMM0ZYUE93NXJMU1MyOFFteVRVcmdQOElTTVR2OE54OFdqQWt4eFRXNFZQZC05NndYU0ZKbFdZMW9PVkhJQ1hEVmZiQXlfSG5jMVFVUDB2X3ZGUmRvVm5EV3F6Q2JVM0htaC1MRWNJdmVCdFJLUTBqakwteVB6b2JvVmE2Z1RxWHhOc28wZnBLZEpoSF9HdW1FTGlYMXE1RVJnNXZwMTBhR001cS1vUzg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNWTYtOWJpM1VtblZnYW41T0JCSU5leV9LUVRFbjBHUGdFME9KcGNIcFh3bjhOM0JrRjNiZUlqNjE0a2lEaGVuZWhLYmhXbGx4Z29zWVRRMFFKMzJRdTFYajdGQlM3SmZvU0V4RW9rZTA2Y1NGRlEwWDJsaW52REhnNXRvaE9qTVdERXZvMHBGTVJLZmVPd0ROUm9yLUtEM2t6c29mVFFMN3ZCLUZOSFctVTdCaUdvUzNoeVlkRHM0a084WTl4?oc=5", "source_name": "TradingView", "published_at": "2026-05-27T18:32:00+00:00", "published_display": "27 May 2026 18:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS2hZNlZ0aE1aUndpc2RTZEIxMm5GZ0doWF8taF9ZRjVUYmJVVHBOdk1HaU1TTk9NZ2RQOHZqX2hRTElWU1h1UXpzbjJ5QjdnMWNuSVR0S0d4SHFWOEZBRzNXcHBmRS1GZjZ3QTdVTTZKZFZ1SlFCZmVWLWVEMmhrTXpkRE5sQVZxSjN4SXVGZWhlVUJFOFY5dDE2VkZBRDVzak1jZ1BVMG5LMFVqcU9fMXF5aDExVUxSYTlaSkJR?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Intellia Therapeutics (NTLA) Pricing Reflect Its Gene Editing Potential After Recent Price Surge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMzNzcUhBOXducUtuZHZfXzNHRnRSbUlpNjd0WU5XV0FWMlg3ZTZwZk5GY2dKTHpVYzhJQW5CRjlqd3Nvei03SFpLU05DdE9WYVJNUmxidUhYTFJKZVVZZ1R3Nk9uUm5jLVhQdFVaWVduWnZaallZVUo0bXZTUnZBNmktNG1rT1Q1Ml9TUVpXWHVkdklkbkFxWkR3ZVhJRngzd1VjNXp0aw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOYW42Wnd1SDlRT3hRdHFOMnN4MHdPTHVDSF8yV3hqN2hMdkdTcnR1cU1VSHk0T3JZVDNpcUNWYXRaV1dxbUZlR0hkUVNwRnZ0RG90dFZESEsyZFNtb2VHalE2SkFJWUUtRVk2dDVvOHBYdnlCaEllMVMxY3hBLWVJVkJSdzVZdFJPd1dYRmZhb2V5OWRjb2xCRkh4dm1TSVpYQlp6RXNKWjZrR3dRM3NzUnBWM3pxcTE3QjlxLVR4Y2xYX1U5Wlc3cnJnQVNwRElmZGl3Sml6aw?oc=5", "source_name": "Barchart.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOel91dHlYOUs0ek9ZQlJVNWV5UFpmUFFkY2JRSW5Kdi1ITTVHcHVnSW1ENGg0WVhNbkFqb0xsMTh2UGpkcnk2Y2xpSjJPQnN0RlQzS3RFS242LUFlWFpRekw1Qk12eGw1cmU1VlRHbEJfMWJpQnU4RHFXOHlzYnc2R3BPdWktWEdsZmhfNm5lZ0YtQ2ZPVlJRWl96eUh1UjE5dUtnWFdSa0MzRF9DN0gybEludTdUaENM?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNUkFoN09nZjJLNHlMSHl4OWI2REkxVS1XZjk0UmVTV0EwSWZMWVJvMTFCVHllUjhFQ3VqOENwX3dDbC1uUDFVMkVFR2E3azNUWjFJb1RJOWx3VUdhUF9fcE5KMW5sS19VOEJYQzIyUUI2WDlvUEFid1Y3cWRQLUctZk54TWNTVENYY2hya2M0R1RIb3hkNHVpVE5DLW5ZenIzTVNLcGN0WDlVWnh2cUFHVTlGX3ZJLWdGNkNfM29NSXNuWDRsRkduck00RjdJWEVOQW5MTXhWOWlVOTVlV2lVNFVR?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-11T07:00:00+00:00", "published_display": "11 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUXFVWDRTVWFhT1FndVBhTkZsay1ES1VhYU9jS3VkN2liWURiX09YMFlFRmllSm1wNW13R3F1OG9BTlFGcmJmaHNvTV9acWZSWVFTWXpySkR0R2tGTjRjUHBvR3JiZlJhcGUwclNwRlBpMF9scEtuT0duT255bzAzQzItUktLQXREWkY4M3U5M2VoX0d6VUp1S013N282WUxNbTVzXzR6SC1UOVo5cmQzV05YUDVtaVVKcWllRFJtRFM?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMnFmUldtWXRfdEFBYUpSWW8wdE5SRjZzQmpsVmRpNlBZc2FRQU1wQWttQXJoLVFENm1ENUR3eF9zMkRGQy1VdmV1cXhleDRJTk13OXdHM1dUeXQydnptSUswdWlyY0VTQU5FbXJCWTFlZzRTWHRxaV85X2s0RHhYUFRsVGJVQWIxSnVQalVXZF9YNjBBcnZfSXk4b3c2eGxVV1gyNXhveTRaQ0R6eUstT3NQZ3BXcWZhYW5tVl93?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA places clinical hold on Intellia's gene therapy trials; shares fall", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb0F0cTZGSjl0MTlkX3luV3JDanZUbTdFYnRQV2lyU1hJNUFlckZnSEI2YThkNVl6MFQwX2tyNll4OGdVV21vMUkwTUcwQXRMNmhCczl3cDlNUWNmUlNoWVlNVjIyeWdNY25mNXJOeEdOREZ0eDhmYi1oNkNPTGxLRWlJelFpTTRaeU9HejFuQjh2UlM2QzVramxtYnBzaExCS1NRRklyV1FsZXA3RkRJa2ZaZjcwalNiSlZjXzdmOVQxdXY3T3h6d2M2TnNNU2VLSHF0c0NldTNKcEU?oc=5", "source_name": "Reuters", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-18T07:00:00+00:00", "published_display": "18 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright \u2013 Check Out The Details", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOOEwtSTNWRS0zdENieHNiR3EtX2F1VDc2ZnVSelNmaXNXalUzUGpwSFptYUxGdDlmLVFNU3V0QkZzNG9wc0V2S1lIMFZiTDFrakU1eURwSWY0dHVHWWpOdjQ0RmhFUmZFcmNNNnVZWjhnSnVyejA1LWFqdlVUeHlJNEZrRER2SWFrSXNjbnBYcTlnOHdfRG5VZWRZakNvWGNYenhvbzJZUEdlZDVLdk1TOWgwN2tPNTRiSlNqanFuLVJEMTVoQUtnc1BVYzBFQQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-18T07:00:00+00:00", "published_display": "18 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOSEhIMHl0Xzd3R1BUbEFZVVlNSDE3THFsUnRXem54akl1YWNnSUxDa3JHZWd4YlFlaUs4a3JnNVNaRGx6MTR3N1N3by1UWHJtZFBzTlEyUFBVbW4tLUhJV1JRaFh4QTE5R05CSTZOZlN3OWFhdC1PUnFBNHVjbzJsVGR4ZHFNOS1NVTFMQ0VjbFMxM1dBSUpxdWFjUEhLU3hhZjZkeHlFeVIxUXFVZG9wM0pFSkd3eEJYLVZSTlY1VjU0X25xWFU5dG5B?oc=5", "source_name": "Stocktwits", "published_at": "2026-06-22T08:45:11+00:00", "published_display": "22 Jun 2026 08:45", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "StockWatch: Positive Phase III Data Sells Investors on Intellia", "summary": "Intellia Therapeutics' shares surged after positive Phase III data for its gene-editing candidate, lonvoguran ziclumeran (lonvo-z), in hereditary angioedema (HAE). The therapy met primary and secondary endpoints, leading analysts to anticipate FDA approval and strong market adopt", "url": "https://www.genengnews.com/topics/translational-medicine/stockwatch-positive-phase-iii-data-sells-investors-on-intellia/", "source_name": "Genetic Engineering and Biotechnology News", "published_at": "2026-06-22T00:40:24", "published_display": "22 Jun 2026 00:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNOGN5ekxXVGRDQkVHYXI1ZERGYm91aG1GRHpSY2RKeGF4N0J1UXJ2TVJYaEc1Z3lnSG9kUXE4bHRCRHJmajYxOU00LUdDenh0LU5ETXJZdVQ0ZllUZHVIV1I0X0c3Qm9QNmx6UmZEeFREWFZia0psaTVzbkRacHVHVUdoVjRrcXplOXM0VWtoWWNQamh3WC0zTGs3WGgtaXA3bHM1blpqTFB3R3phNUxVR0tn?oc=5", "source_name": "Kavout", "published_at": "2026-06-21T22:42:58+00:00", "published_display": "21 Jun 2026 22:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Is Up 29.4% After New Phase 3 Lonvo-z Data and FDA Filing", "summary": "Intellia Therapeutics (NTLA) shares surged 29.4% following positive Phase 3 HAELO trial data for its CRISPR therapy, lonvo-z, targeting hereditary angioedema. The company also filed a rolling biologics license application with the FDA and published results in the New England Jour", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-up-294-after-new-phase-3-lonvo", "source_name": "Simply Wall Street", "published_at": "2026-06-21T20:39:36", "published_display": "21 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/d1b7d197-3672-3b18-947e-fbf48989e2a9/intellia-therapeutics-vs..html", "source_name": "Motley Fool", "published_at": "2026-06-20T15:22:04+00:00", "published_display": "20 Jun 2026 15:22", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Stock Could Be 41.2% Undervalued After Phase 3 HAE Data", "summary": "Intellia Therapeutics (NTLA) is drawing attention after releasing positive Phase 3 HAELO trial data for its CRISPR-based therapy lonvo-z in hereditary angioedema and submitting a rolling biologics license application to the FDA. Despite a recent 70.14% year-to-date share price in", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-stock-could-be-412-undervalued-af/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-19T23:09:04", "published_display": "19 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Sees 10.7% Surge in Stock Price", "summary": "Intellia Therapeutics (NTLA) saw a significant stock price surge of 10.7% on June 17, 2026, driven by increased investor confidence in its CRISPR/Cas9 gene-editing technology. Despite a solid GF Score\u2122 of 72, indicating strong growth prospects, the company's low profitability ran", "url": "https://www.gurufocus.com/news/8920894/intellia-therapeutics-ntla-sees-107-surge-in-stock-price?mobile=true", "source_name": "GuruFocus", "published_at": "2026-06-17T20:09:38", "published_display": "17 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NTLA Stock Climbs As Phase 3 CRISPR Data Turn Heads", "summary": "Intellia Therapeutics Inc. (NTLA) stock surged by 10.24% following promising Phase 3 CRISPR gene-editing trial results for its drug lonvo-z, aimed at hereditary angioedema. The data, published in the New England Journal of Medicine and presented at EAACI 2026, showed significant ", "url": "https://stockstotrade.com/news/intellia-therapeutics-inc-ntla-news-2026_06_17/", "source_name": "StocksToTrade", "published_at": "2026-06-17T17:42:16", "published_display": "17 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia\u2019s gene editor \u2018keeps pace\u2019 with Ionis in hereditary angioedema", "summary": "Intellia Therapeutics' CRISPR-based gene editing therapy, lonvo-z, showed significant efficacy in a Phase 3 study for hereditary angioedema, reducing disease attack episodes by 89% and moderate/severe attacks by 91%. Analysts predict lonvo-z could challenge Ionis Pharmaceuticals'", "url": "https://www.biospace.com/drug-development/intellias-gene-editor-keeps-pace-with-ionis-in-hereditary-angioedema", "source_name": "BioSpace", "published_at": "2026-06-16T22:40:18", "published_display": "16 Jun 2026 22:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up", "summary": "Intellia Therapeutics (NTLA) shares surged 23.2% after announcing additional positive data from its phase III HAELO study for lonvo-z, an HAE gene-editing therapy. The latest data showed lonvo-z significantly reduced the monthly rates of HAE attacks, further demonstrating its pot", "url": "https://www.tradingview.com/news/zacks:3c8d58e84094b:0-ntla-posts-strong-additional-phase-iii-data-from-hae-study-stock-up/", "source_name": "TradingView", "published_at": "2026-06-16T14:39:09", "published_display": "16 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?", "summary": "Intellia Therapeutics (NTLA) shares surged 23.2% after", "url": "https://au.finance.yahoo.com/news/strength-seen-intellia-therapeutics-ntla-124300834.html", "source_name": "Market source", "published_at": "2026-06-16T12:43:00", "published_display": "16 Jun 2026 12:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)", "summary": "This article highlights recent analyst ratings for several healthcare companies. Wells Fargo maintained a Hold rating on Incyte (INCY), while TD Cowen and William Blair reiterated Buy ratings for Intellia Therapeutics (NTLA). Wells Fargo also maintained a Hold rating on Halozyme ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/INCY/pressreleases/2489035/analysts-conflicted-on-these-healthcare-names-incyte-incy-intellia-therapeutics-ntla-and-halozyme-halo/", "source_name": "The Globe and Mail", "published_at": "2026-06-16T10:39:09", "published_display": "16 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Skyrockets 23% on Encouraging Lonvo-Z Results", "summary": "Intellia Therapeutics saw its share price jump 23% following positive Phase 3 results for its hereditary angioedema (HAE) treatment, Lonvo-Z. The drug achieved an 87% reduction in monthly attacks compared to placebo and demonstrated favorable safety, with 62% of patients being at", "url": "https://finance.yahoo.com/healthcare/articles/intellia-therapeutics-ntla-skyrockets-23-024604431.html", "source_name": "Market source", "published_at": "2026-06-16T03:10:41", "published_display": "16 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Surges; Can Its Gene-Editing Drug Solve The Chronic Treatment Problem?", "summary": "", "url": "https://finance.yahoo.com/m/724376ea-3984-3ab1-9ac0-3ce9b78fd1fe/intellia-surges%3B-can-its.html", "source_name": "Investor's Business Daily", "published_at": "2026-06-15T21:10:35+00:00", "published_display": "15 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics options trading jumps to 7,041 contracts By Investing.com", "summary": "Intellia Therapeutics Inc.'s options trading volume significantly increased to 7,041 contracts on Monday morning, with call options representing the majority of the activity. The June 18, 2026 $13 and $14 call options saw substantial contract volumes. Shares of Intellia Therapeut", "url": "https://ng.investing.com/news/stock-market-news/intellia-therapeutics-options-trading-jumps-to-7041-contracts-93CH-2558703", "source_name": "Investing.com Nigeria", "published_at": "2026-06-15T16:09:26", "published_display": "15 Jun 2026 16:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Maintains Intellia Therapeutics(NTLA.US) With Sell Rating, Maintains Target Price $9", "summary": "Goldman Sachs has reiterated its Sell rating for Intellia Therapeutics (NTLA.US), keeping the target price at $9. This indicates a continued bearish outlook from the investment bank on the company's stock.", "url": "https://www.moomoo.com/news/post/71545619/goldman-sachs-maintains-intellia-therapeutics-ntlaus-with-sell-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-15T16:09:26", "published_display": "15 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder", "summary": "Intellia Therapeutics' gene-editing therapy, lonvo-z (previously NTLA-2002), has shown promising results in its Phase 3 HAELO trial for hereditary angioedema (HAE), demonstrating an 87% reduction in monthly HAE attacks compared to placebo. The data, presented at EAACI 2026 and pu", "url": "https://www.benzinga.com/analyst-stock-ratings/analyst-color/26/06/53194250/intellias-one-time-gene-editing-therapy-gains-ground-against-rivals-in-rare-swelling-disorder", "source_name": "Benzinga", "published_at": "2026-06-15T14:09:26", "published_display": "15 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia touts \u2018paradigm-shifting\u2019 phase 3 data for one-time HAE treatment", "summary": "Intellia Therapeutics has released additional positive phase 3 data for its one-time gene-editing therapy, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE). The results showed significant reductions in HAE attacks and improvements in quality of life, meeting secon", "url": "https://www.fiercebiotech.com/biotech/intellia-shares-paradigm-shifting-ph-3-data-one-time-treatment-hae-patients", "source_name": "Fierce Biotech", "published_at": "2026-06-15T10:37:00", "published_display": "15 Jun 2026 10:37", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is NTLA Stock Jumping 5% Premarket Today?", "summary": "Intellia Therapeutics (NTLA) stock surged 5% premarket after releasing additional Phase 3 data for its CRISPR-based hereditary angioedema (HAE) treatment, Lonvo-z. The data showed an 89% reduction in attacks requiring rescue medication and significant quality-of-life improvements", "url": "https://stocktwits.com/news-articles/markets/equity/why-is-ntla-stock-jumping-premarket-today/cZKfOwMR7dV", "source_name": "Stocktwits", "published_at": "2026-06-15T08:14:37", "published_display": "15 Jun 2026 08:14", "sentiment": "positive", "sentiment_pct": 92, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Intellia Therapeutics (NTLA) Is Down 10.6% After Advancing Lonvo-z Toward FDA Review And Commercialization", "summary": "Intellia Therapeutics (NTLA) recently reported positive Phase 3 results for its gene-editing therapy, lonvo-z, for hereditary angioedema and has initiated a rolling biologics license application with the FDA. Despite this significant progress towards potential commercialization, ", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/why-intellia-therapeutics-ntla-is-down-106-after-advancing-l", "source_name": "Simply Wall Street", "published_at": "2026-06-14T12:39:54", "published_display": "14 Jun 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) down 7.9% since last earnings report: Can it rebound?", "summary": "This article discusses the recent performance of Intellia Therapeutics (NTLA), noting a 7.9% decline since its last earnings report. The piece poses the question of whether the stock can rebound from this downturn.", "url": "https://www.msn.com/en-us/money/topstocks/intellia-therapeutics-ntla-down-79-since-last-earnings-report-can-it-rebound/ar-AA25jckm", "source_name": "MSN", "published_at": "2026-06-13T20:39:54", "published_display": "13 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 28, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema", "summary": "Intellia Therapeutics announced additional positive Phase 3 results for lonvoguran ziclumeran (lonvo-z), its CRISPR-based investigational treatment for hereditary angioedema (HAE). The data from the HAELO clinical trial, presented at EAACI 2026 and published in The New England Jo", "url": "https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-reports-additional-positive-phase-3", "source_name": "Intellia Therapeutics", "published_at": "2026-06-13T12:09:42", "published_display": "13 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 95, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Reports Additional Positive Phase 3 Results For Lonvoguran Ziclumeran (Lonvo-Z)", "summary": "Intellia Therapeutics announced additional positive Phase 3 results for its drug Lonvoguran Ziclumeran (Lonvo-Z). The announcement indicates progress for the company in its clinical trials. The news is brief and provided by Refinitiv.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_TUA8CD8VW:0-intellia-therapeutics-says-haleo-met-its-primary-endpoint-with-an-87-reduction-p-0-0001-in-mean-monthly-attacks-in-lonvo-z-arm/", "source_name": "TradingView", "published_at": "2026-06-13T11:09:42", "published_display": "13 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "One-time CRISPR gene edit cuts HAE attacks by 87% in Phase 3 trial", "summary": "Intellia Therapeutics reported additional positive Phase 3 HAELO data for its CRISPR gene-editing treatment, lonvo-z, showing an 87% reduction in mean monthly hereditary angioedema (HAE) attacks compared to placebo. The trial also demonstrated a significant improvement in quality", "url": "https://www.stocktitan.net/news/NTLA/intellia-therapeutics-reports-additional-positive-phase-3-results-afks73wvycew.html", "source_name": "Stock Titan", "published_at": "2026-06-13T11:09:42", "published_display": "13 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploring High Growth Tech Stocks In The US Market", "summary": "This article identifies and discusses high-growth tech stocks in the US market, noting the market's recent decline but overall annual growth. It highlights key companies like LightPath Technologies, Intellia Therapeutics, and AppLovin, detailing their financial performance, growt", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/exploring-high-growth-tech-stocks-in-the-us-market-25/amp", "source_name": "Simply Wall Street", "published_at": "2026-06-11T11:12:19", "published_display": "11 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) director Muna Bhanji granted 9,200 RSUs and 13,300 options", "summary": "Intellia Therapeutics (NTLA) director Muna Bhanji was granted 9,200 Restricted Stock Units (RSUs) and 13,300 stock options, as detailed in a recent Form 4 filing. The RSUs increase her direct common stock holdings to 36,403 shares, while the stock options have an exercise price o", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-013839da4612.html", "source_name": "Stock Titan", "published_at": "2026-06-11T07:39:32", "published_display": "11 Jun 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Goff Brian", "summary": "This article is a Form 4 statement from Intellia Therapeutics, detailing changes in beneficial ownership of securities for Director Brian Goff, as required by the SEC.", "url": "https://www.moomoo.com/news/notice/307505294/intellia-therapeutics-4-statement-of-changes-in-beneficial-ownership-of", "source_name": "Moomoo", "published_at": "2026-06-11T04:10:05", "published_display": "11 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) director Georgia Keresty receives stock awards and options grant", "summary": "Intellia Therapeutics director Georgia Keresty received equity compensation, including 9,200 restricted stock units (RSUs) and stock options for 13,300 shares at an exercise price of $12.89 per share. Following these grants, her direct holdings in common stock increased to 41,083", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-ff1dd5f15e40.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:10:05", "published_display": "10 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) director receives 9,200 RSUs and 13,300 options", "summary": "Intellia Therapeutics director Frank Verwiel was granted 9,200 restricted stock units (RSUs) and a stock option for 13,300 shares, reflecting new equity awards rather than open-market transactions. Following these grants, Verwiel directly holds 35,148 common shares and the new st", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-9db79714028e.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:10:05", "published_display": "10 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) director receives 9,200 RSUs and 13,300 stock options", "summary": "Intellia Therapeutics director Fred E. Cohen was granted 9,200 restricted stock units and a stock option for 13,300 shares, according to a recent SEC Form 4 filing. The RSUs increase his direct common stock holdings to 216,653 shares, while the stock option has an exercise price ", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-8502e3800dbb.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:10:05", "published_display": "10 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) director awarded RSUs and stock options in new grant", "summary": "Intellia Therapeutics director William J. Chase received new equity awards on June 9, 2026, comprising 9,200 restricted stock units and stock options for 13,300 shares at an exercise price of $12.89. The stock options vest fully on the earlier of one year from the grant date or t", "url": "https://www.stocktitan.net/sec-filings/NTLA/form-4-intellia-therapeutics-inc-insider-trading-activity-3c9b98311aa4.html", "source_name": "Stock Titan", "published_at": "2026-06-10T23:10:05", "published_display": "10 Jun 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics, Inc. (NTLA) Buy Rating Reiterated Despite Share Offering Dilution", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNNXR5dFRBNkk0Q3NRTWpzQzNka2xSQTJDWi1vbkhybDExc0EzVGtkQXJIRGo5Y3Q4STlqbUZwREJhNVlsN050Q1dEOEdJUWRGTHVJZnZIUS0zSVptUzQtT1RKWl9LRkRNOHZ3akhqSDNoYjRiZFFZOHNtbkZMU1BKazhxZjNVdXJmT1BhcGZReUotQVR0UzhkVDZ3U1c2SE5LaTBOMnNn?oc=5", "source_name": "Market source", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia (NTLA) Rockets 13% Ahead of Phase 3 Lonvo-Z Study Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOTnMzbWZrVlVJMGhsdXc4aGpjdXp0c2pZSnMyTGl2MTRWRHVONDcxNXNlc0FUVWdET1BWR2NJdzFLUkZrUDdaU0lVcUE4eU9YU09HYTBzYlVwck80cVNON2llckx5Wk1IbUtrMHRsYlZWdk9XZWs1RTJjYVJGZzdtMEtmY2hRU2E2LWlWS0tMaERsN1JhcFNhMHVVSEZoX1hQ?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPa2JqcDFJbXFMM0ZYUE93NXJMU1MyOFFteVRVcmdQOElTTVR2OE54OFdqQWt4eFRXNFZQZC05NndYU0ZKbFdZMW9PVkhJQ1hEVmZiQXlfSG5jMVFVUDB2X3ZGUmRvVm5EV3F6Q2JVM0htaC1MRWNJdmVCdFJLUTBqakwteVB6b2JvVmE2Z1RxWHhOc28wZnBLZEpoSF9HdW1FTGlYMXE1RVJnNXZwMTBhR001cS1vUzg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-31T07:00:00+00:00", "published_display": "31 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNWTYtOWJpM1VtblZnYW41T0JCSU5leV9LUVRFbjBHUGdFME9KcGNIcFh3bjhOM0JrRjNiZUlqNjE0a2lEaGVuZWhLYmhXbGx4Z29zWVRRMFFKMzJRdTFYajdGQlM3SmZvU0V4RW9rZTA2Y1NGRlEwWDJsaW52REhnNXRvaE9qTVdERXZvMHBGTVJLZmVPd0ROUm9yLUtEM2t6c29mVFFMN3ZCLUZOSFctVTdCaUdvUzNoeVlkRHM0a084WTl4?oc=5", "source_name": "TradingView", "published_at": "2026-05-27T18:32:00+00:00", "published_display": "27 May 2026 18:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQS2hZNlZ0aE1aUndpc2RTZEIxMm5GZ0doWF8taF9ZRjVUYmJVVHBOdk1HaU1TTk9NZ2RQOHZqX2hRTElWU1h1UXpzbjJ5QjdnMWNuSVR0S0d4SHFWOEZBRzNXcHBmRS1GZjZ3QTdVTTZKZFZ1SlFCZmVWLWVEMmhrTXpkRE5sQVZxSjN4SXVGZWhlVUJFOFY5dDE2VkZBRDVzak1jZ1BVMG5LMFVqcU9fMXF5aDExVUxSYTlaSkJR?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Intellia Therapeutics (NTLA) Pricing Reflect Its Gene Editing Potential After Recent Price Surge", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPMzNzcUhBOXducUtuZHZfXzNHRnRSbUlpNjd0WU5XV0FWMlg3ZTZwZk5GY2dKTHpVYzhJQW5CRjlqd3Nvei03SFpLU05DdE9WYVJNUmxidUhYTFJKZVVZZ1R3Nk9uUm5jLVhQdFVaWVduWnZaallZVUo0bXZTUnZBNmktNG1rT1Q1Ml9TUVpXWHVkdklkbkFxWkR3ZVhJRngzd1VjNXp0aw?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps Buying", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOYW42Wnd1SDlRT3hRdHFOMnN4MHdPTHVDSF8yV3hqN2hMdkdTcnR1cU1VSHk0T3JZVDNpcUNWYXRaV1dxbUZlR0hkUVNwRnZ0RG90dFZESEsyZFNtb2VHalE2SkFJWUUtRVk2dDVvOHBYdnlCaEllMVMxY3hBLWVJVkJSdzVZdFJPd1dYRmZhb2V5OWRjb2xCRkh4dm1TSVpYQlp6RXNKWjZrR3dRM3NzUnBWM3pxcTE3QjlxLVR4Y2xYX1U5Wlc3cnJnQVNwRElmZGl3Sml6aw?oc=5", "source_name": "Barchart.com", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Proposed Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOel91dHlYOUs0ek9ZQlJVNWV5UFpmUFFkY2JRSW5Kdi1ITTVHcHVnSW1ENGg0WVhNbkFqb0xsMTh2UGpkcnk2Y2xpSjJPQnN0RlQzS3RFS242LUFlWFpRekw1Qk12eGw1cmU1VlRHbEJfMWJpQnU4RHFXOHlzYnc2R3BPdWktWEdsZmhfNm5lZ0YtQ2ZPVlJRWl96eUh1UjE5dUtnWFdSa0MzRF9DN0gybEludTdUaENM?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Adopts Fourth Amended and Restated Bylaws", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4gFBVV95cUxNUkFoN09nZjJLNHlMSHl4OWI2REkxVS1XZjk0UmVTV0EwSWZMWVJvMTFCVHllUjhFQ3VqOENwX3dDbC1uUDFVMkVFR2E3azNUWjFJb1RJOWx3VUdhUF9fcE5KMW5sS19VOEJYQzIyUUI2WDlvUEFid1Y3cWRQLUctZk54TWNTVENYY2hya2M0R1RIb3hkNHVpVE5DLW5ZenIzTVNLcGN0WDlVWnh2cUFHVTlGX3ZJLWdGNkNfM29NSXNuWDRsRkduck00RjdJWEVOQW5MTXhWOWlVOTVlV2lVNFVR?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-04-11T07:00:00+00:00", "published_display": "11 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxOUXFVWDRTVWFhT1FndVBhTkZsay1ES1VhYU9jS3VkN2liWURiX09YMFlFRmllSm1wNW13R3F1OG9BTlFGcmJmaHNvTV9acWZSWVFTWXpySkR0R2tGTjRjUHBvR3JiZlJhcGUwclNwRlBpMF9scEtuT0duT255bzAzQzItUktLQXREWkY4M3U5M2VoX0d6VUp1S013N282WUxNbTVzXzR6SC1UOVo5cmQzV05YUDVtaVVKcWllRFJtRFM?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQMnFmUldtWXRfdEFBYUpSWW8wdE5SRjZzQmpsVmRpNlBZc2FRQU1wQWttQXJoLVFENm1ENUR3eF9zMkRGQy1VdmV1cXhleDRJTk13OXdHM1dUeXQydnptSUswdWlyY0VTQU5FbXJCWTFlZzRTWHRxaV85X2s0RHhYUFRsVGJVQWIxSnVQalVXZF9YNjBBcnZfSXk4b3c2eGxVV1gyNXhveTRaQ0R6eUstT3NQZ3BXcWZhYW5tVl93?oc=5", "source_name": "Intellia Therapeutics", "published_at": "2025-11-06T08:00:00+00:00", "published_display": "06 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA places clinical hold on Intellia's gene therapy trials; shares fall", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNb0F0cTZGSjl0MTlkX3luV3JDanZUbTdFYnRQV2lyU1hJNUFlckZnSEI2YThkNVl6MFQwX2tyNll4OGdVV21vMUkwTUcwQXRMNmhCczl3cDlNUWNmUlNoWVlNVjIyeWdNY25mNXJOeEdOREZ0eDhmYi1oNkNPTGxLRWlJelFpTTRaeU9HejFuQjh2UlM2QzVramxtYnBzaExCS1NRRklyV1FsZXA3RkRJa2ZaZjcwalNiSlZjXzdmOVQxdXY3T3h6d2M2TnNNU2VLSHF0c0NldTNKcEU?oc=5", "source_name": "Reuters", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-18T07:00:00+00:00", "published_display": "18 Sep 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Intellia Therapeutics Stock Gets A Price Target Hike From HC Wainwright \u2013 Check Out The Details", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxOOEwtSTNWRS0zdENieHNiR3EtX2F1VDc2ZnVSelNmaXNXalUzUGpwSFptYUxGdDlmLVFNU3V0QkZzNG9wc0V2S1lIMFZiTDFrakU1eURwSWY0dHVHWWpOdjQ0RmhFUmZFcmNNNnVZWjhnSnVyejA1LWFqdlVUeHlJNEZrRER2SWFrSXNjbnBYcTlnOHdfRG5VZWRZakNvWGNYenhvbzJZUEdlZDVLdk1TOWgwN2tPNTRiSlNqanFuLVJEMTVoQUtnc1BVYzBFQQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-09-18T07:00:00+00:00", "published_display": "18 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 56, "sentiment_summary": {"positive": 26, "negative": 5, "neutral": 25, "score": 60, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 14.65, "count": 26}, {"event": "earnings", "label": "Earnings", "weight": 10.59, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.0, "count": 3}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 26, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 15.67, "latest_week": "2026-06-19", "one_week_move": 29.4, "four_week_move": 24.4, "twelve_week_move": 26.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.083135, "market_dynamics_buy_signal": false, "relative_strength": 0.045417, "fair_value_gap": -18.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 45.4264, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+29.4% over one week, +24.4% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 69, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "simplywall.st", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "Intellia Therapeutics", "count": 5}, {"label": "Simply Wall Street", "count": 4}, {"label": "Stocktwits", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "The Globe and Mail", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 26}, {"label": "Earnings", "count": 21}, {"label": "Analyst action", "count": 4}, {"label": "Regulatory and legal", "count": 3}, {"label": "Macro sensitivity", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "60/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+29.4% over one week, +24.4% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Nasdaq, S&P 500 Futures Edge Lower Ahead Of Fed Week, AI Earnings Test: Why POET, ATOM, OGN, QCOM, NTLA Are In Focus"}], "updated_at": "2026-06-23T02:16:20.564661+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}